Clinical Trial

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 7, 2024 (before its estimated January 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
A pragmatic, two armed, study comparing 2 standard doses of an anti-cancer drug called bevacizumab, given in combination with Chemotherapy. The study will be offered to ovarian cancer patients whose disease is platinum chemotherapy resistant . Higher doses of anti-cancer based drugs are not always better than lower doses and can cause more side effects without improvement of cancer. These patients will be randomly assigned either 7.5 mg/kg or 15mg/kg of bevacizumab combined with chemotherapy . Comparing these two doses will determine if the lower dose-level is non-inferior, and could lead to practice changes.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-03-05; most recent amendment 2024-08-06.
Status change: Not Yet Recruiting → Recruiting 2023-07-25
Trial Details
NCT Number NCT04787289
Lead Sponsor British Columbia Cancer Agency
Conditions Ovarian Cancer, Platinum-resistant Ovarian Cancer
Enrollment 244 participants
Start Date 2021-09-10
Primary Completion 2025-01-31 (estimated)
Study Completion 2025-01-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-07